• K V Kozlov, O V Maltsev, K V Kasyanenko, V S Sukachev, A V Saulevich, S S Karyakin, A D Dubrovin, and R N Smirnov.
• Kirov Military Medical Academy.
• Terapevt Arkh. 2024 Dec 16; 96 (11): 103510411035-1041.

AimTo evaluate the efficacy of the antiviral drug riamilovir (trade name - «Triazavirin®») for the prevention of SARS-CoV-2 infection (COVID-19) and other acute respiratory viral infections in young people from organized groups.Materials And MethodsThe study involved 386 individuals aged 18-22 years: 199 received riamilovir at a daily dose of 250 mg for 15 days, while 187 did not receive prophylactic drugs. For 30 days, disease occurrence was monitored among volunteers. In case of illness, the duration, severity of clinical manifestations, complications, and pathogen elimination dynamics were assessed via PCR from nasopharyngeal and oropharyngeal swabs.ResultsDuring riamilovir administration, a statistically significant reduction in cases of acute respiratory viral infections of non-coronavirus etiology was observed, with no COVID-19 cases reported, confirmed by the absence of SARS-CoV-2 RNA in this group. The shortest duration of acute respiratory viral infections was noted in patients taking the prophylactic drug.ConclusionRiamilovir (trade name - «Triazavirin®») showed statistically significant prophylactic efficacy during its administration in an organized group. Its use decreased the frequency of detection of viral pathogens and resulted in milder acute respiratory disease, likely due to reduced viral load in individuals.

31 keywords...

hide…